Amarantus Subsidiary Elto Pharma Announces the Iss
Post# of 30028
(Total Views: 354)
Posted On: 12/08/2017 10:33:24 AM
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033
San Francisco, CA -- December 8, 2017 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned, neurology-focused subsidiary Elto Pharma, Inc. was granted patents in Singapore and New Zealand covering the therapeutic use of Eltoprazine for the treatment of motor symptoms associated with Parkinson’s disease therapies. In New Zealand Patent No. 702730 was issued, and in Singapore Patent No. 11201408240T was issued. Both patents are titled “Treatment of Motor Symptoms and Movement Disorder Side Effects Associated with Parkinson’s disease treatments,” and are valid into 2033.
Elto Pharma is currently redesigning its Phase 2b clinical study for Eltoprazine in the treatment of Parkinson’s disease Levodopa-induced dyskinesia (PD-LID), targeted to begin enrollment in 2018. Eltoprazine has received Orphan Drug Designation from the US FDA for Eltoprazine in the treatment of PD-LID.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS’ wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS’ wholly-owned subsidiary Cutanogen Corporation. AMBS’ wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.
Patents extend Eltoprazine Parkinson’s disease LID treatment exclusivity into 2033
San Francisco, CA -- December 8, 2017 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies, today announced that its wholly-owned, neurology-focused subsidiary Elto Pharma, Inc. was granted patents in Singapore and New Zealand covering the therapeutic use of Eltoprazine for the treatment of motor symptoms associated with Parkinson’s disease therapies. In New Zealand Patent No. 702730 was issued, and in Singapore Patent No. 11201408240T was issued. Both patents are titled “Treatment of Motor Symptoms and Movement Disorder Side Effects Associated with Parkinson’s disease treatments,” and are valid into 2033.
Elto Pharma is currently redesigning its Phase 2b clinical study for Eltoprazine in the treatment of Parkinson’s disease Levodopa-induced dyskinesia (PD-LID), targeted to begin enrollment in 2018. Eltoprazine has received Orphan Drug Designation from the US FDA for Eltoprazine in the treatment of PD-LID.
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS’ wholly-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult ADHD. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS’ wholly-owned subsidiary Cutanogen Corporation. AMBS’ wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard. AMBS also owns approximately 80 million shares of Avant Diagnostics, Inc. via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that occurred in May 2016.
(4)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼